SCHEMBL2190696

SCHEMBL2190696

Cc1cccc(CN2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.63
KDM4E B2RXH2 3/20 0.63
MAPT P10636 1/20 0.63
HTR7 P34969 3/20 0.59
CYP3A4 P08684 2/20 0.59
USP2 O75604 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C19 P33261 1/20 0.59
HPN P05981 1/20 0.59
CHRM2 P08172 1/20 0.59
ADRA2A P08913 1/20 0.59
ADORA3 P0DMS8 1/20 0.59
CHRM1 P11229 1/20 0.59
DRD2 P14416 1/20 0.59
ADRA2C P18825 1/20 0.59
CNR1 P21554 1/20 0.59
DRD1 P21728 1/20 0.59
DRD4 P21917 1/20 0.59
SLC6A2 P23975 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL588394 0.87 SIGMAR1 (0.67) ALDH1A1KDM4EMAPTHTR7DRD4
Hydrochloric Acid SCHEMBL587708 0.85 SIGMAR1 (0.65) ALDH1A1KDM4EHTR7DRD4LMNA
SCHEMBL20415963 0.84 ALDH1A1 (0.83) ALDH1A1KDM4EMAPTCYP3A4USP2
SCHEMBL2194377 0.80 HTR7 (0.63) ALDH1A1KDM4EMAPTHTR7MEN1
Hydrochloric Acid SCHEMBL9859525 0.79 HTR7 (0.62) ALDH1A1KDM4EMAPTHTR7MEN1
SCHEMBL2190477 0.79 LMNA (0.58) ALDH1A1KDM4EHTR7ADORA3DRD2
SCHEMBL19145578 0.79 HTR7 (0.81) ALDH1A1KDM4EMAPTHTR7DRD4
SCHEMBL4754254 0.78 HTR7 (0.71) ALDH1A1KDM4EMAPTHTR7CYP2D6
SCHEMBL1138135 0.77 HTR7 (0.60) ALDH1A1KDM4EMAPTHTR7DRD2
SCHEMBL3988740 0.76 HTR7 (0.58) ALDH1A1KDM4EMAPTHTR7KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040122021-A1 Enantiomers of 1-[(4-chlorophenyl)phenylmethyl)-4-[(4-methylphenyl)sulfonyl) piperazine COSSEMENT ERIC (BE) 2004-06-24 US claimed
US-20040122023-A1 Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine COSSEMENT ERIC (BE) 2004-06-24 US claimed
EP-0955295-B1 Therapeutically active levorotatory and dextrorotatory 1-((4-chlorophenyl)phenylmethyl) piperazines UCB SA (BE) 2004-05-19 EP claimed
US-20030204089-A1 Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine COSSEMENT ERIC (BE) 2003-10-30 US claimed
US-20030013692-A1 Methods of treating neurological disorders GULLANS STEVEN R (US) 2003-01-16 US claimed
WO-2002056892-A2 METHODS OF TREATING NEUROLOGICAL DISORDERS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2002-07-25 WO claimed
EP-0955295-A1 Therapeutically active levorotatory and dextrorotatory 1-((4-chlorophenyl)phenylmethyl) piperazines UCB, S.A. (BE) 1999-11-10 EP claimed
EP-0617028-A1 Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine U C B, S.A. (BE) 1994-09-28 EP claimed
WO-2024029173-A1 AGENT FOR PREVENTING OR AMELIORATING OSTEOPOROSIS 国立大学法人東海国立大学機構 2024-02-08 WO disclosed
US-20180208566-A1 Deuterated Meclizine CONCERT PHARMACEUTICALS, INC. 2018-07-26 US disclosed
EP-2985024-A1 THERAPEUTIC AGENT FOR SYSTEMIC BONE DISEASE AND USE THEREOF National University Corporation Nagoya University (JP) 2016-02-17 EP disclosed
US-20150216860-A1 THERAPEUTIC AGENT FOR SYSTEMIC BONE DISEASE AND USE THEREOF NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2015-08-06 US disclosed
US-20110172425-A1 NOVEL WATER BASED PROCESS FOR THE PREPARATION OF SUBSTITUTED DIPHENYLMETHYL PIPERAZINES CALYX CHEMICALS AND PHARMACEUTICALS PVT. LTD. (IN) 2011-07-14 US disclosed
US-7482022-B2 Palatable chewable tablet PFIZER INC. (US) 2009-01-27 US disclosed
EP-0994710-B1 PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION, COMPRISING A BENZHYDRYLPIPERAZINE AND A CYCLODEXTRIN UCB SA (BE) 2002-09-25 EP disclosed
US-6436942-B1 ADMINISTERING THE ANTIHISTAMINE, CETIRIZINE, PRODUCED FROM THIS INTERMEDIATE OF HIGH OPTICAL PURITY UCB, S.A. (BE) 2002-08-20 US disclosed
EP-0617028-B1 Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl)sulfonyl] piperazine UCB SA (BE) 2000-06-14 EP disclosed
EP-0955295-A1 Therapeutically active levorotatory and dextrorotatory 1-((4-chlorophenyl)phenylmethyl) piperazines UCB, S.A. (BE) 1999-11-10 EP disclosed
US-5478941-A Useful in treatment of asthma, allergies, inflammation and anxiety; antihistaminic activity U C B, S.A. (BE) 1995-12-26 US disclosed
EP-0617028-A1 Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine U C B, S.A. (BE) 1994-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122021-A1 Enantiomers of 1-[(4-chlorophenyl)phenylmethyl)-4-[(4-methylphenyl)sulfonyl) piperazine RPLP1, QDPR, RPLP2 ALDH1A1 224/4885KDM4E 954/4885MAPT 2824/4885
US-20030204089-A1 Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine RPLP1, QDPR, PRLHR ALDH1A1 187/4885KDM4E 993/4885MAPT 2993/4885
US-20040122023-A1 Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine RPLP1, QDPR, PRLHR ALDH1A1 187/4885KDM4E 993/4885MAPT 2993/4885
US-20180208566-A1 Deuterated Meclizine FGFR3, FGFR1, FGFR2 ALDH1A1 2118/4885KDM4E 3313/4885MAPT 2040/4885
US-20110172425-A1 NOVEL WATER BASED PROCESS FOR THE PREPARATION OF SUBSTITUTED DIPHENYLMETHYL PIPERAZINES ALK, WIZ, HACL2 ALDH1A1 310/4885KDM4E 2018/4885MAPT 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.